# Jazz Pharmaceuticals plc (JAZZ) FY2026 Q2 P&L / Income Statement

- Company: Jazz Pharmaceuticals plc (JAZZ)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001232524-26-000045
- Page: https://plicit.ai/financials/jazz/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/jazz-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (12 categories)

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (12 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 1,208,300,000 US dollars
- **Total operating expenses**: 960,100,000 US dollars
- **Income (loss) from operations**: 248,200,000 US dollars
- **Other income (expense), net (calculated)**: negative 37,200,000 US dollars
- **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 211,000,000 US dollars
- **Income tax expense (benefit)**: 18,100,000 US dollars
- **Net income (loss)**: 192,800,000 US dollars
- **Epidiolex/Epidyolex**: 292,100,000 US dollars
- **Zepzelca**: 105,800,000 US dollars
- **Rylaze/Enrylaze**: 99,500,000 US dollars
- **Defitelio/defibrotide**: 62,000,000 US dollars
- **Modeyso**: 48,200,000 US dollars
- **Vyxeos**: 31,400,000 US dollars
- **Ziihera**: 15,400,000 US dollars
- **Other**: 0 US dollars
- **Xywav**: 471,200,000 US dollars
- **Xyrem**: 30,500,000 US dollars
- **High-sodium oxybate AG royalty revenue**: 42,200,000 US dollars
- **Other royalty and contract revenues**: 10,000,000 US dollars
- **Cost of product sales (excluding amortization of acquired developed technologies)**: 116,400,000 US dollars
- **Selling, general and administrative**: 389,200,000 US dollars
- **Research and development**: 207,500,000 US dollars
- **Intangible asset amortization**: 170,000,000 US dollars
- **Gain on sale of priority review voucher**: 0 US dollars
- **Acquired in-process research and development**: 77,000,000 US dollars
- **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/jazz/fy2026-q2-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/jazz-fy2026-q2-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 1,208,300,000 US dollars
- **Total operating expenses**: 960,100,000 US dollars
- **Income (loss) from operations**: 248,200,000 US dollars
- **Other income (expense), net (calculated)**: negative 37,200,000 US dollars
- **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 211,000,000 US dollars
- **Income tax expense (benefit)**: 18,100,000 US dollars
- **Net income (loss)**: 192,800,000 US dollars
- **Product sales, net**: 1,156,100,000 US dollars
- **Royalties and contract revenues**: 52,200,000 US dollars
- **Cost of product sales (excluding amortization of acquired developed technologies)**: 116,400,000 US dollars
- **Selling, general and administrative**: 389,200,000 US dollars
- **Research and development**: 207,500,000 US dollars
- **Intangible asset amortization**: 170,000,000 US dollars
- **Gain on sale of priority review voucher**: 0 US dollars
- **Acquired in-process research and development**: 77,000,000 US dollars
- **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/jazz/fy2026-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/jazz-fy2026-q2-revenue-by-geography-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 1,208,300,000 US dollars
- **Total operating expenses**: 960,100,000 US dollars
- **Income (loss) from operations**: 248,200,000 US dollars
- **Other income (expense), net (calculated)**: negative 37,200,000 US dollars
- **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 211,000,000 US dollars
- **Income tax expense (benefit)**: 18,100,000 US dollars
- **Net income (loss)**: 192,800,000 US dollars
- **UNITED STATES**: 1,077,900,000 US dollars
- **Europe**: 97,400,000 US dollars
- **All other**: 33,000,000 US dollars
- **Cost of product sales (excluding amortization of acquired developed technologies)**: 116,400,000 US dollars
- **Selling, general and administrative**: 389,200,000 US dollars
- **Research and development**: 207,500,000 US dollars
- **Intangible asset amortization**: 170,000,000 US dollars
- **Gain on sale of priority review voucher**: 0 US dollars
- **Acquired in-process research and development**: 77,000,000 US dollars
- **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.